The serological prevalence of SARS‐CoV‐2 infection in patients with chronic myeloid leukemia is similar to that in the general population

BACKGROUND: Patients with hematological malignancies are at an increased risk of SARS‐CoV‐2 disease (COVID‐19) and adverse outcome. However, a low mortality rate has been reported in patients with chronic myeloid leukemia (CML). Preclinical evidence suggests that tyrosine kinase inhibitors (TKIs) ma...

Descripción completa

Detalles Bibliográficos
Autores principales: Bonifacio, Massimiliano, Tiribelli, Mario, Miggiano, Maria Cristina, Abruzzese, Elisabetta, Binotto, Gianni, Scaffidi, Luigi, Cordioli, Maddalena, Damiani, Daniela, Di Bona, Eros, Trawinska, Malgorzata Monika, Tanasi, Ilaria, Dubbini, Maria Vittoria, Velotta, Vanessa, Ceccarelli, Giulia, Pierdomenico, Elisabetta, Lo Schirico, Mariella, Semenzato, Gianpietro, Ruggeri, Marco, Fanin, Renato, Tacconelli, Evelina, Pizzolo, Giovanni, Krampera, Mauro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8446554/
https://www.ncbi.nlm.nih.gov/pubmed/34464516
http://dx.doi.org/10.1002/cam4.4179

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8446554/
https://www.ncbi.nlm.nih.gov/pubmed/34464516
http://dx.doi.org/10.1002/cam4.4179

Ejemplares similares